Back to top
more

MeiraGTx (MGTX)

(Real Time Quote from BATS)

$7.83 USD

7.83
184,791

+0.09 (1.16%)

Updated Aug 6, 2025 02:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Icosavax, Inc. (ICVX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -1.61% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Certara, Inc. (CERT) Matches Q1 Earnings Estimates

by Zacks Equity Research

Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 1.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -66% and 66.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -31.03% and 14.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vanda Pharmaceuticals (VNDA) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of -54.55% and 3.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -42.86% and 39.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of -3.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Gritstone bio Inc. (GRTS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of -3.03% and 16.38%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Horizon Therapeutics (HZNP) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 16.52% and 2.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) Stock Jumps 6.5%: Will It Continue to Soar?

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 55.10% and 202.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avid Bioservices (CDMO) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 80% and 12.53%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bluebird Bio (BLUE) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of 0% and 79.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -13.46% and 38.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q3 Earnings Expected to Decline

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

by Kinjel Shah

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 13.21% and 13.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -25.58% and 83.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MeiraGTx (MGTX) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

MeiraGTx Holdings (MGTX) has been struggling lately, but the selling pressure may be coming to an end soon

Zacks Equity Research

Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q4 Earnings Expected to Decline

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tirthankar Chakraborty headshot

New Strong Buy Stocks For July 10th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.